Core Laboratories NV (CLB)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Core Laboratories NV.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 5 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 10.60 $ — 9% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
4 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 2.4% failed
- More than 10% revenue growth is expected for the coming year 5.2% failed
- Share count grows by less than 3% a year -0.2% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 4.7% failed
- Gross margin at 40% or higher and without meaningful erosion 17.9% failed
- Goodwill from acquisitions does not grow faster than revenue 18.1% passed
- Net debt below twice EBITDA 2.0 x EBITDA passed
- Operating cash flow covers the profits of the last three years 20 m passed
- Return on capital at 15% or higher, or up versus two years ago 10.6% failed
- Insiders hold at least 10% or are net buyers 1.4% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 46.2% above the current price.
- Consensus
- Hold
- Analyst Ratings
- 5
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 0.43 | 0.37 – 0.49 | 511 | -42.7% | 2 |
| 12/31/2027 | 0.68 | 0.58 – 0.77 | 540 | 57.0% | 2 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.15 | 235.10 | 129 | 0.80 | 5.70 | 21 | 16 |
| 2025: Q1 | 0.00 | -104.90 | 124 | -4.70 | -0.10 | 7 | 3 |
| 2025: Q2 | 0.22 | 18.30 | 130 | -0.30 | 8.20 | 15 | 10 |
| 2025: Q3 | 0.30 | 23.10 | 135 | 0.10 | 10.60 | 9 | 6 |
| 2025: Q4 | 0.11 | -31.30 | 138 | 7.00 | 3.60 | 8 | 4 |
| 2026: Q1 | -0.02 | – | 122 | -1.40 | -0.60 | 4 | -1 |
| 2026: Q2 | 0.13 | -40.90 | 125 | -4.30 | 4.80 | 8 | 3 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 595 | 86 | 64 | 1.45 | 132 | 155 | 573 |
| 2017 | 660 | 112 | 83 | 1.88 | 124 | 149 | 585 |
| 2018 | 701 | 119 | 80 | 1.79 | 112 | 161 | 649 |
| 2019 | 668 | 97 | 102 | 2.28 | 90 | 178 | 775 |
| 2020 | 487 | -77 | -98 | -2.17 | 58 | 72 | 569 |
| 2021 | 470 | 45 | 20 | 0.42 | 37 | 156 | 581 |
| 2022 | 490 | 42 | 19 | 0.42 | 25 | 184 | 578 |
| 2023 | 510 | 55 | 37 | 0.77 | 25 | 225 | 586 |
| 2024 | 524 | 59 | 31 | 0.66 | 56 | 252 | 590 |
| 2025 | 527 | 50 | 30 | 0.64 | 37 | 266 | 584 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Core Laboratories Inc. bietet Dienstleistungen und Produkte zur Reservoirbeschreibung und Produktionssteigerung für die Öl- und Gasindustrie in den USA und international an.
| Employees | 3,300 |
|---|---|
| Headquarters | Houston, TX |
| Address | 6316 Windfern Road, 77040 Houston, United States |
| Phone | 713 328 2673 |
| Website | corelab.com |
| IPO Date | 20. Sep 1995 |
| ISIN | US21867A1051 |
| Stock Split | 2:1 on 07/09/2010 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Lawrence V. Bruno | Chairman of the Board, CEO, President & COO | 1960 |
| Christopher Scott Hill | Senior VP & CFO | 1970 |
| Gwendolyn Y. Gresham M.B.A. | Senior Vice President of Corporate Development & Investor Relations | 1968 |
| Mark Damian Tattoli J.D. | Senior VP, Secretary & General Counsel | 1972 |
| Sow Hang Teo | VP, Treasurer & Chief Accounting Officer | 1970 |
| Leslie D. Linklater | Vice President of People, Organization & Culture | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.